We found that with blockade of PD-1 with nivolumab (a humanized IgG4 monoclonal antibody targeting PD-1) on PTD 7, when the LLC cell inoculation–induced pain hypersensitivity had not developed, both hyperalgesia and allodynia were evoked in the tumor-affected limb. This evidence concerns the gene PDCD1 and neoplasm.